Broad routine use

Safety in routine use has been demonstrated through several haemovigilance programmes evaluating >300,000 platelet transfusions.

• French National Haemovigilance programme - ANSM
• Swiss National Haemovigilance programme - Swissmedic
• Cerus Multicenter Haemovigilance programme

Safety in routine use has also been demonstrated in different patient populations such as cardiovascular patients, haematology/oncology patients, and neonatal and paediatric patients.

When transfusing INTERCEPT-treated platelet concentrates, you know that safety and efficacy have been validated in routine conditions in first-rate haemovigilance programmes.